P3 Health Partners Inc

P3 Health Partners, Inc. is a population health care management company, which engages in the provision of professional support services to doctors and clinicians. The firm offers capital efficient care model, data and technology, physician leadership and community outreach tools to create enhanced patient outcomes and experiences. The company was founded by Sherif Abdou and Amir Bacchus on August 20, 2020 and is headquartered in Henderson, NV.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

P3 Health Partners Inc reports robust Q4 performance and eyes profitability in 2024

P3 Health Partners Inc demonstrated strong financial performance and strategic initiatives during the Q4 2022 earnings call, positioning the company for future growth and profitability. While facing challenges in managing costs and optimizing margins, the company remains optimistic about its financial outlook and growth prospects. By leveraging opportunities in market expansion and operational enhancements, P3 Health Partners Inc aims to achieve positive cash flow in 2024.

P3 Health Partners Inc reports improved Q1 performance and growth outlook

P3 Health Partners Inc showed improved financial performance and operational metrics in Q1.
The company is on track towards profitability, with a focus on growth and healthcare transformation.
Challenges include managing EBITDA losses, COVID impact, and provider relationships.
Opportunities lie in further improving metrics, expanding in newer markets, and enhancing care management.

P3 Health Partners Inc reports strong Q2 earnings and growth opportunities

P3 Health Partners Inc (PIII) demonstrated positive financial performance in Q2 2023, with strong revenue growth and improved margins.
The company's focus on operational efficiency, quality improvements, and growth objectives positions it well for future success.
While facing challenges in managing expenses and achieving profitability, P3 Health Partners Inc (PIII) has opportunities for growth and market expansion.
Overall, the company's sustained demand, efficient operations, and progress towards profitability indicate a promising outlook for stakeholders.

P3 Health Partners Inc reports solid Q3 results, eyes growth

P3 Health Partners Inc delivered a strong performance in Q3, focusing on revenue growth, cost management, and profitability.
While facing challenges such as timing issues and payer negotiations, the company remains optimistic about its future prospects.
Opportunities for growth include expanding partnerships, optimizing operational efficiency, and providing clearer financial guidance to stakeholders.
Overall, PIII's strategic initiatives position it well for continued success, with a positive outlook for 2024 and beyond.

P3 Health Partners reports strong 2023 growth and positive 2024 outlook

P3 Health Partners Inc delivered robust financial performance in 2023.
Strategic initiatives led to improved margins and revenue growth.
Challenges include managing expenses and potential regulatory changes.
Opportunities lie in partnerships, persistency rates, and revenue expansion.

P3 Health Partners reports strong Q1 earnings, eyes AI growth

P3 Health Partners Inc's Q1 2024 showed strong revenue growth and operational efficiencies.
The company is confident in achieving its EBITDA guidance through strategic partnerships and focus on high-risk populations.
Challenges include managing cash flow, capital requirements for growth, and effective high-risk population management.
Opportunities lie in AI partnerships, data analytics tools, and deeper provider engagement for better care outcomes.

P3 Health Partners reports robust Q2 results and eyes growth

P3 Health Partners showed strong performance in Q2 with revenue growth, cost reduction, and improved EBITDA loss. The company's focus on expense management and balance sheet strength position it well for future growth. Challenges remain in managing medical costs and achieving profitability, but opportunities for expansion and improved financial performance are evident.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HENDERSON, Nev., June 27, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced it has been added as a member of the Russell 3000® Index, effective after the U.S. market opens on June 27, as part of the 2022 Russell indexes reconstitution.

P3 Health Partners Announces Inclusion in the Russell 3000® Index

HENDERSON, Nev., May 24, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that on May 18, 2022, it received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market ( “Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Form 10-K”) or its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 (the “2022 First Quarter Form 10-Q”) with the Securities and Exchange Commission (the “SEC”). As previously disclosed in the Company's Current Report on Form 8-K filed with the SEC on April 25, 2022 and its form 12b-25 filed with the SEC on May 16, 2022, the Company is currently completing a restatement related to the Company's consolidated financial statements for the years ended December 31, 2020 and 2019 and unaudited condensed consolidated financial statements for the interim quarterly periods ended September 30, 2021, June 30, 2021, March 31, 2021, September 30, 2020, June 30, 2020 and March 31, 2020.

P3 Health Partners Announces Receipt of Nasdaq Notice Regarding Late Filing of Periodic Reports

Management to Host Conference Call and Webcast April 25, 2022 at 4:30 PM ET Management to Host Conference Call and Webcast April 25, 2022 at 4:30 PM ET

P3 Health Partners to Present Fourth Quarter and Full Year 2021 Financial Results

P3 Health Partners Inc (NASDAQ: PIII) expects Q4 FY21 revenue of approximately $183 million, up 46% Y/Y, beating the consensus of $171 million. For FY21, the Company sees sales increase 32% to approximately $642 million.

P3 Health Partners Expects To Clock 46% Jump In Q4 Sales, FY22 Guidance Surpass Consensus

HENDERSON, Nev., March 07, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners, Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced the Company's participation in the following investor conferences in March:

P3 Health Partners to Participate at Upcoming Investor Conferences

Eyenovia

loanDepot

MannKind

Oncternal Therapeutics Inc

Performant Financial

Pixelworks

Vaccinex Inc

Penny stocks to buy now according to insiders. The post 8 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 Penny Stocks To Buy Now According To Insiders In 2022

Insiders are scooping up shares of these penny stocks in 2022. The post 5 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy Now According To Insiders In 2022

Acquisition brings more than 10,500 Medicare Advantage members and marks P3's fifth state of operation Acquisition brings more than 10,500 Medicare Advantage members and marks P3's fifth state of operation

P3 Health Partners Expands to California, Closes Acquisition of Medcore HP and Omni IPA Medical Group, Inc.

HENDERSON, Nev., Dec. 29, 2021 (GLOBE NEWSWIRE) -- P3 Health Partners Inc. (NASDAQ: PIII, or “P3”), a patient-centered and physician-led population health management company, today announced that its Chief Executive Officer, Dr. Sherif Abdou, and members of the P3 management team will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 5:15 p.m. (ET) / 2:15 p.m. (PT). The appearance will be webcast live and can be accessed in the Events & Presentations section of the P3 investor website. A replay will be available on the Company's website following the event.

P3 Health Partners Announces Participation at the 40th Annual J.P. Morgan Healthcare Conference

P3 Health Partners to Begin Trading December 6th on the Nasdaq Under Ticker Symbol “PIII” P3 Health Partners to Begin Trading December 6th on the Nasdaq Under Ticker Symbol “PIII”

P3 Health Partners Closes Business Combination with Foresight Acquisition Corp. and Will Begin Trading on the Nasdaq

News for P3 Health Partners Inc Stock (PIII)